{"filing":{"accession_number":"0001193125-26-241930","cik":"0001598646","ticker":"NERV","company_name":"Minerva Neurosciences, Inc.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"d119518d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1598646/000119312526241930/d119518d8k.htm"},"events":[{"id":8757,"run_id":7686,"accession_number":"0001193125-26-241930","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Minerva Neurosciences entered into an at-the-market (ATM) offering agreement with Leerink Partners on May 27, 2026, authorizing the issuance and sale of up to $75.0 million in common stock shares under its S-3 registration statement.","company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":1940,"accession_number":"0001193125-26-241930","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Minerva Neurosciences entered into an at-the-market (ATM) offering agreement with Leerink Partners on May 27, 2026, authorizing the issuance and sale of up to $75.0 million in common stock shares. ATM offerings are a form of registered equity issuance that can be dilutive to existing shareholders and are material to investors assessing capital structure and ownership dilution. The filing explicitly references the S-3 registration statement and prospectus supplement governing the offering.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:17:03.414281+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":8758,"run_id":7686,"accession_number":"0001193125-26-241930","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"Minerva announced a material modification to the Phase 3 C19 trial design for roluperidone, extending the relapse assessment phase from 40 weeks to 52 weeks following FDA feedback, which extends the expected timeline for relapse data delivery to H2 2028.","company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":1941,"accession_number":"0001193125-26-241930","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a material modification to the Phase 3 C19 trial design for roluperidone, extending the relapse assessment phase from 40 weeks to 52 weeks following FDA feedback. This trial design change affects the timeline and scope of a lead product candidate's clinical development, which would impact investor assessment of regulatory pathway and commercialization prospects. While not a traditional earnings release, M\u0026A activity, or executive change, the modification to a pivotal Phase 3 trial represents a material event affecting the company's development strategy and expected data delivery timeline (now extending relapse data to H2 2028).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:17:03.414281+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1940,"accession_number":"0001193125-26-241930","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Minerva Neurosciences entered into an at-the-market (ATM) offering agreement with Leerink Partners on May 27, 2026, authorizing the issuance and sale of up to $75.0 million in common stock shares. ATM offerings are a form of registered equity issuance that can be dilutive to existing shareholders and are material to investors assessing capital structure and ownership dilution. The filing explicitly references the S-3 registration statement and prospectus supplement governing the offering.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:17:03.414281+00:00","company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","filing_date":"2026-05-27"},{"id":1941,"accession_number":"0001193125-26-241930","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces a material modification to the Phase 3 C19 trial design for roluperidone, extending the relapse assessment phase from 40 weeks to 52 weeks following FDA feedback. This trial design change affects the timeline and scope of a lead product candidate's clinical development, which would impact investor assessment of regulatory pathway and commercialization prospects. While not a traditional earnings release, M\u0026A activity, or executive change, the modification to a pivotal Phase 3 trial represents a material event affecting the company's development strategy and expected data delivery timeline (now extending relapse data to H2 2028).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:17:03.414281+00:00","company_name":"Minerva Neurosciences, Inc.","ticker":"NERV","filing_date":"2026-05-27"}]}